section name header

Indications ⬇

BEERS REMS


Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: edema, HF, hypertension, MI, vasculitis

Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), EXFOLIATIVE DERMATITIS, ↑sweating, photosensitivity, pruritus, rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS

EENT: abnormal vision, tinnitus

GI: abdominal pain, diarrhea, anorexia, constipation, dry mouth, dyspepsia, flatulence, gastritis, gastroenteritis, GI BLEEDING, ↑liver enzymes, nausea, stomatitis, vomiting

GU: albuminuria, azotemia, interstitial nephritis

Hemat: prolonged bleeding time

Metab: ↑appetite, weight gain

Neuro: agitation, anxiety, confusion, depression, dizziness, drowsiness, fatigue, headache, insomnia, malaise, paresthesia, STROKE, tremor, weakness

Resp: dyspnea, hypersensitivity pneumonitis

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Relafen, Relafen DS

Action ⬆ ⬇

  • Inhibits prostaglandin synthesis.
Therapeutic effects:
  • Suppression of pain and inflammation.

Classifications ⬆ ⬇

Therapeutic Classification: antirheumatics, nonopioid analgesics

Pharmacologic Classification: nonsteroidal anti inflammatory drugs nsaids

Pharmacokinetics ⬆ ⬇

Absorption: Nabumetone (a prodrug) is 80% absorbed after oral administration; 35% is rapidly converted to 6-methoxy-2-naphthylacetic acid (6-MNA), which is the active drug.

Distribution: Unknown.

Protein Binding: >99%.

Metabolism/Excretion: 6-MNA is metabolized by the liver to inactive compounds.

Half-Life: 24 hr (↑ in severe renal impairment).

Time/Action Profile ⬆ ⬇

(analgesia/anti-inflammatory effects)

ROUTEONSETPEAKDURATION
PO1–2 daysfew days–2 wk12–24 hr



Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆

na-BYOO-me-tone